Drug news

FDA will review cabozantinib (Exelixis Inc) as a treatment for Thyroid Ccancer on 29 November 2012

Read time: 1 mins

Last updated:2nd Aug 2012

Published:2nd Aug 2012

Source: Pharmawand

Exelixis, Inc.announced that the FDA has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary Thyroid Cancer (MTC). The FDA also granted priority review designation to the NDA for cabozantinib. The Prescription Drug User Fee Act (PDUFA) action date is November 29, 2012.

Learning Zone Homepage

Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers

Discover assorted resources and expert opinions on molecular diagnostics for RET inhibition in non-small cell lung cancer (NSCLC) and thyroid cancers.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approves Takhzyro (lanadelumab) to include children with hereditary angioedema (HAE) as young as 2 years of age

The European Commission has expanded the approval of Takhzyro (lanadelumab) to include children with hereditary angioedema (HAE) as young as 2 years of age

1 mins

Drug news

Medtronic launches Penditure LAA exclusion system in the United States

Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures

1 min

Drug news

Positive results from DREAMM-7 head-to-head phase III trial for Blenrep (belantamab mafodotin) in relapsed/refractory multiple myeloma

GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma

1 min

See all news